Bettonville: When you look at the pipeline of new therapies and diagnostics coming to market, this is really Sci-Fi stuff and presents real care delivery challenges – It’s not as simple as a new pill is approved and we distribute it through your local pharmacy.

When we're talking about advanced cell therapies, often these involve extraction of your own blood cells, sending them to the lab, reengineering them, distributing them back to the patient and re-infusing them. It's a very complicated bioengineering process that needs to be delivered in legacy care settings. When we talk about radiopharmaceuticals where we're infusing patients with active radioisotopes in place of, or in addition to, particle accelerator radiation therapy, these have to be delivered in lead vaults in the basement of health care systems.

When you talk about pan-cancer blood tests, these often can have ambiguous results that require a reinvention of our system for screening cancer in order to handle long-term surveillance of borderline disease. There’s so much innovation happening in the biotechnology pipeline, and every one of those requires a rethinking of some process of delivering care once it comes to market. The FDA approval isn't the end of the process – it’s really the beginning of us standing up a new treatment regimen. I think over the next decade, bringing all of those to market and all of the complexities that come with them – getting them to the right patients, because many of them are extremely expensive – is going to be a real challenge in the field of cancer care delivery.

‘Sci-Fi Stuff’: Yosemite Investor Matt Bettonville On Emerging Oncology Tech

More from Oncology

More from Device Area